Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
Not Applicable (4)
P 4 (1)

Trial Status

Unknown4
Recruiting2
Not Yet Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07444060Recruiting

Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease

NCT05387031Recruiting

Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease

NCT06725563Not ApplicableNot Yet Recruiting

Endoscopically Placed Lumen-Apposing Metal Stents for the Treatment of Symptomatic Intestinal Strictures in Individuals With Inflammatory Bowel Disease

NCT05009212Not ApplicableUnknown

Endoscopic Stricturotomy Versus Endoscopic Balloon Dilatation in Patients With Crohn's Disease and Symptomatic Small Bowel Stricture

NCT04865484Not ApplicableUnknown

Prospective Randomized Comparative Study of the Treatment of Multisegmental Fibrostenosing Crohn's Disease.

NCT03222011Not ApplicableUnknown

Stricture Definition and Treatment (STRIDENT) Endoscopic Therapy Study

NCT03220841Phase 4Unknown

Stricture Definition and Treatment (STRIDENT) Drug Therapy Study

Showing all 7 trials

Research Network

Activity Timeline